Global Checkpoint Inhibitors Market Growth Rate
The global checkpoint inhibitors market is expected to decline from $15.44 billion in 2019 to $15.20 billion in 2020 at a compound annual growth rate (CAGR) of -1.50%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $29.77 billion in 2023 at a CAGR of 25.11%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the checkpoint inhibitors market during the forecast period. However, the high cost of checkpoint inhibitor cancer treatment is expected to limit the checkpoint inhibitor market. The pressure to contain costs and demonstrate value is widespread.
The checkpoint inhibitors market consists of sales of the immune checkpoint inhibitor drugs and related services by entities that produce checkpoint inhibitors for treating cancer. A checkpoint inhibitor is a drug that blocks proteins that stop the body’s immune system from killing the cancer cells. One type of cell in the immune system that fights the cancer cells are T-cells. T cells have proteins on them that turn on immune response and other proteins that turn it off. These are called checkpoints. Some checkpoints help T-cells to become active while others help T-cells to switch off. When cancer cells produce high levels of proteins, the switch off checkpoints restrict the immune responses from being strong and sometimes even stops the T-cells from killing the cancer cells. When the checkpoints are blocked by the checkpoint inhibitor from binding with its partner proteins, this allows the T-cells to kill the cancer cells.
Request For A Sample For The Global Checkpoint Inhibitors Market Report:
The global checkpoint inhibitors market is further segmented based on type and geography.
By Drug: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Others
By Application: Lung Cancer, Renal Cancer, Blood Cancer, Bladder Cancer, Melanoma, Others
By Geography: The global checkpoint inhibitors market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.
Read More On The Report For The Global Checkpoint Inhibitors Market At:
Trends In The Checkpoint Inhibitors Market
Major companies in the checkpoint inhibitor market are forming partnerships or collaborations for the development of advanced technologies such as bifunctional fusion protein or Y-trap. Bifunctional fusion protein or Y-trap is a therapy that was developed in 2018. Most of the patients with cancer do not respond to immune checkpoint inhibitors, thus these make immunotherapies more effective.
Checkpoint Inhibitors Global Market Report 2020 is one of a series of new reports from The Business Research Company that provides checkpoint inhibitors market overviews, analyzes and forecasts checkpoint inhibitors market size and growth for the global checkpoint inhibitors market, checkpoint inhibitors market share, checkpoint inhibitors market players, checkpoint inhibitors market size, checkpoint inhibitors market segments and geographies, checkpoint inhibitors market trends, checkpoint inhibitors market drivers and checkpoint inhibitors market restraints, checkpoint inhibitors market’s leading competitors’ revenues, profiles and market shares. The checkpoint inhibitors market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.